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Preterm infants are at a higher risk for developing 
nutritional compromise because of limited nutrient 
reserves, immature gastrointestinal function, and 
greater nutrient demands. The introduction of 
parenteral nutrition (PN) in early postnatal life has 
improved their mortality and morbidity and is 
now widely used in neonatal intensive care units 
(NICUs). However, prolonged PN is associated with 
a wide spectrum of hepatobiliary derangements, 
and cholestasis is a major complication in preterm 
infants. Parenteral nutrition-associated cholestasis 
(PNAC) is defined as cholestasis (conjugated bil-
irubin ≥ 2.0 mg/dL) that is associated with a pro-
longed duration of PN administration (usually > 2 
weeks).1,2 Accurate diagnosis should be made only 
after other known causes of cholestasis have been 
excluded.
In this issue of Pediatrics and Neonatology, Hsieh 
et al retrospectively reviewed 62 preterm infants 
who received PN for at least 14 days and who were 
admitted to their NICU between 2004 and 2007.3 
Their reported incidence of PNAC was 17.74% 
(11 infants), which is comparable with another re-
port in Taiwan.4 The authors found that the most 
significant risk factor and predictor for the devel-
opment of PNAC was the duration of PN. The cut-off 
point estimated by ROC curve was 61 days. Because 
the duration is too long to serve as a good predic-
tor, the authors concluded that low energy intake 
during the 2nd and 3rd weeks of life can be a predic-
tor of PNAC.
Although PNAC has been well documented for 
more than 30 years, the precise etiology is still not 
fully understood.1,5 The pathogenesis is considered 
to be multifactorial, and includes hepatic immatu-
rity, loss of enteral feeding, sepsis, and PN toxins 
and/or deficiencies.6 The high prevalence of PNAC 
in younger age groups, particularly premature in-
fants, suggests the pathogenic role of immature 
organ functions, such as the biliary secretory system, 
decreased bile acid pool, impaired hepatic mito-
chondrial function, and enterohepatic circulation.5 
The duration of PN is also related to the severity of 
histopathological changes in the liver. In an autopsy 
series, Zambrano et al found that, while the dura-
tion was < 2 weeks, no fibrosis or only mild fibrosis 
was observed. However, in the patients who received 
PN for more than 6 weeks, moderate-to-severe 
hepatic fibrosis developed.7 The risk associated with 
longer duration of PN exposure was also observed 
in clinical studies, as highlighted in this paper.3
In 1975, Rager and Finegold reported intrahe-
patic cholestasis in 9 out of 15 premature infants 
who received PN.8 This observation was the first 
indication that lack of enteral intake may contrib-
ute to PNAC. Enteral starvation could subsequently 
lead to the lack of cholecystokinin release, decreased 
emptying of the gallbladder, followed by bile stasis 
and depletion of the enterohepatic circulation.1,5,9 
Hypoplasia of enterocytes and impaired gut immu-
nity also contribute to PNAC via inflammatory path-
ways. In the current study, the risk of delayed enteral 
feeding was reflected by the low energy intake 
during the 2nd and 3rd weeks of life.3 The investiga-
tors’ results further support the protective effect 
of early enteral feeding.
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Sepsis has a crucial role in the development of 
PNAC. The requirement for central line placement 
for PN infusion, bacterial overgrowth caused by 
enteral starvation and immature immune function 
facilitate the occurrence of infection. The risk of 
sepsis, which has been observed both clinically and 
in animal models,1,4,6,10 is also reported in this study. 
Although metronidazole and tetracycline therapy 
seemed to be beneficial in rodent models,10,11 the 
clinical data in humans are limited.12,13
The components of PN also contribute to the 
pathogenesis of PNAC, including taurine and carni-
tine deficiency, aluminum and manganese toxicity, 
and oxidant imbalance.5,6 The caloric excess caused 
by glucose and lipid overload may lead to elevated 
transaminase levels and hepatic steatosis. The 
protein content in PN is also associated with liver 
toxicity. One previous study reported that prema-
ture infants who received PN formulations with 
higher protein content (3.6 g/kg) developed cholesta-
sis earlier than those who received 2.5 g/kg daily.14 
In addition, stigmasterol, a phytosterol that is 
prevalent in soy-derived PN lipid solutions, sup-
pressed the expression of bile acid homeostatic 
proteins such as bile salt export pump, fibroblast 
growth factor-19, and organic solute transporter 
α/β.15 There are several recent reports that have 
demonstrated that substituting a fish-oil-based 
lipid for the standard soy-bean preparation may be 
a useful strategy to treat PNAC.16,17 Further ran-
domized controlled studies are warranted to deter-
mine the efficacy and safety of this preparation.
Although effective therapeutic and preventive 
strategies for PNAC have not been established, some 
pilot studies have been reported with encouraging 
results. Ursodeoxycholic acid (UDCA, 10−30 mg/
kg/day) appears to be effective in both a pilot 
study18and retrospective reports, 19,20 and is now 
widely used in NICUs. In one small prospective, 
double-blind, placebo-controlled trial, Arslanoglu 
et al reported that prophylactic use of UDCA in 
preterm infants who received PN could constantly 
and significantly reduce γ-glutamyl transferase 
activity over time.21 This result suggests a preven-
tive role of UDCA and warrants further investiga-
tion. High-dose oral erythromycin, used as prokinetic 
agent, appeared to provide some protection against 
the development of PNAC in a randomized trial in 
preterm infants.22 The treatment was also associ-
ated with an earlier time to achieve full enteral 
feeding and reduce the number of cases with re-
current septicemia. However, the safety profile, 
including the influence of erythromycin on bowel 
microbiota and increased risk of pyloric stenosis, 
should be addressed before evaluating its prophy-
lactic role. The favorable outcomes in these pilot 
studies call for further investigation of a preventive 
strategy for PNAC. Good predictors for the devel-
opment of PNAC in preterm infants, as Hsieh et al 
tried to explore in the current study,3 are impor-
tant in clinical practice.
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